Sergei Grivennikov Receives Second National Cancer Institute R01 Grant for Colorectal Cancer Research

The Grivennikov lab will conduct studies to define the contribution of IL-17B/RB signaling to colorectal cancer, and evaluate its mechanisms of action. The long-term goal is to propose improved colorectal cancer prevention and treatment practices based upon better understanding of molecular predictors of primary and recurrent metastasis.
Earlier this year Grivennikov earned a separate five-year R01 grant from the NCI to determine the contribution of IL-17B/RB signaling to colorectal cancer and evaluate its mechanisms of action.

PHILADELPHIA (November 21, 2018)— For the second time this year, Sergei Grivennikov, PhD, assistant professor in the Cancer Prevention and Control Program at Fox Chase Cancer Center, has received a R01 grant from the National Cancer Institute to support research on the connection between inflammation and colorectal cancer. The grant will provide $2.5 million over five years.

The Grivennikov laboratory studies the molecular and cellular mechanisms underlying how immune and inflammatory pathways promote tumor growth and progression. With this grant, the lab will conduct studies to define the role of microbiota and tumor‑specific microbial stimuli required to control tumor-elicited inflammation in colorectal cancer.

Earlier this year Grivennikov earned a separate five-year R01 grant from the NCI to determine the contribution of IL-17B/RB signaling to colorectal cancer and evaluate its mechanisms of action. The long-term goal of that work is to propose improved colorectal cancer prevention and treatment practices based upon better understanding of molecular predictors of primary and recurrent metastasis.

“We are grateful for this support, and will use this funding to the best of our ability to learn how inflammatory and cancer cells communicate, uncovering new principles and basic mechanisms operating within tumor microenvironment,” Grivennikov said.

Fox Chase Cancer Center (Fox Chase), which includes the Institute for Cancer Research and the American Oncologic Hospital and is a part of Temple Health, is one of the leading comprehensive cancer centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase is also one of just 10 members of the Alliance of Dedicated Cancer Centers. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence six consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. It is the policy of Fox Chase Cancer Center that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.

For more information, call 888-369-2427

Resize Text

Related Articles